Cor­bus brags about an­oth­er PhII suc­cess for its lead drug, but shares slide ear­ly

Cor­bus Phar­ma­ceu­ti­cals has plucked out some pos­i­tive da­ta from its mid-stage cys­tic fi­bro­sis study. But it didn’t help its stock price this morn­ing.

While the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.